AlphaRx and Venturepharm Announce Collaboration Agreement
News Aug 06, 2009
AlphaRx Inc. has announced that the Company has entered into a collaboration agreement with Venturepharm Group to establish a drug development center in China Medical City, Taizhou, China that is expected to be used as a platform for the development of innovative drug products for the fast growing China pharmaceutical market.
The goal of this is to enhance the Company's research capabilities, expedite the development of new products as well as to expand the Company's product range.
Under the terms of the agreement, AlphaRx will incorporate its China R D facility into Venturepharm's state of the art pre-clinical development complex which comprises of a 200,000 sq. ft. chemistry center, a 200,000 sq. ft. multi-product pilot plant to support pilot scale formulation and Clinical Trial Material (CTM) manufacture of biopharmaceutical products and a 500,000 sq. ft. (Asia's largest) animal testing center (under construction).
The in-house pharmaceutical research facilities provide specialized equipment for most aspects of drug research and development. AlphaRx will be responsible for all of its own product development costs and will in turn retain the intellectual property rights relating to any developed products.
Michael Lee, President of AlphaRx, said: "Venturepharm provides the equipment and physical infrastructure to further establish our presence in China and reduces our start up investment costs. As AlphaRx continues to build its presence in China, this collaboration with Venturepharm marks an important step in our overall strategy to commercialize current products and to develop new therapeutics for the world fastest growing pharmaceutical market."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019